[CA19-9 has no value as a tumor marker in obstructive jaundice]
- PMID: 10065510
[CA19-9 has no value as a tumor marker in obstructive jaundice]
Abstract
In the differential diagnosis of pancreatic cancer, CA19-9 appears to be the most sensitive and specific marker currently in use. In the absence of jaundice and at levels greater than 1000 U/ml, the specificity is almost 100%. Levels higher than 1000 U/ml are very uncommon for benign diseases. We report a case of obstructive jaundice due to an impacted stone in the common bile duct with cholangitis, where a CA19-9 level of 61,800 U/ml prompted suspicion of a malignant cause. After treatment the CA19-9 returned to a normal level. One year postoperatively neither abdominal ultrasound nor CT-scan showed any sign of intraabdominal malignancy. Reviewing the literature, we conclude that even very high levels of CA19-9 in cases with obstructive jaundice can be caused by benign diseases. Unlike other tumour markers (alpha-foetoprotein, carcinoembryonic antigen), where exceedingly high levels are definitely caused by malignancy, high levels of CA19-9 can be caused by benign obstructive jaundice. In such cases CA19-9 is useless as a tumour marker. The biliary obstruction must be treated successfully and more diagnostic procedures or even laparotomy performed, to exclude malignancy or treat a benign disease.
Similar articles
-
CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.Am J Surg. 2009 Sep;198(3):333-9. doi: 10.1016/j.amjsurg.2008.12.031. Epub 2009 Apr 17. Am J Surg. 2009. PMID: 19375064
-
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.Eur J Surg Oncol. 2000 Aug;26(5):474-9. doi: 10.1053/ejso.1999.0925. Eur J Surg Oncol. 2000. PMID: 11016469
-
Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.Pancreas. 2006 Oct;33(3):246-9. doi: 10.1097/01.mpa.0000236726.34296.df. Pancreas. 2006. PMID: 17003645
-
CA19-9: the Italian experience.Pancreas. 1994 Nov;9(6):717-9. Pancreas. 1994. PMID: 7846014 Review.
-
Tumour markers in pancreatic cancer.Ann Chir Gynaecol. 1989;78(1):41-53. Ann Chir Gynaecol. 1989. PMID: 2667448 Review.
Cited by
-
A Case of Choledocholithiasis and Obstructive Jaundice With a Very High Serum Carbohydrate Antigen 19-9 (CA 19-9) Level: A Case Report and Review of Literature.Cureus. 2022 Dec 12;14(12):e32447. doi: 10.7759/cureus.32447. eCollection 2022 Dec. Cureus. 2022. PMID: 36644102 Free PMC article.
-
Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.World J Surg. 2009 Apr;33(4):716-22. doi: 10.1007/s00268-008-9853-9. World J Surg. 2009. PMID: 19082654 Free PMC article.
-
[CA 19-9 in the differential diagnosis of pancreatic lesions].Internist (Berl). 2008 Feb;49(2):225-7. doi: 10.1007/s00108-007-1993-8. Internist (Berl). 2008. PMID: 18210015 German.
-
Biochemical profile of bile fluid in patients with malignant cholestasis in comparison with cholestasis due to gall stone.Caspian J Intern Med. 2015 Summer;6(3):165-9. Caspian J Intern Med. 2015. PMID: 26644885 Free PMC article.
-
Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.Yonsei Med J. 2013 May 1;54(3):643-9. doi: 10.3349/ymj.2013.54.3.643. Yonsei Med J. 2013. PMID: 23549809 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical